Treatment with the dopamine precursor L-dopa in patients with Parkinson’s disease reduces insulin secretion in oral glucose tolerance tests [5], but studies in humans do not suggest that diabetes would be a preceding risk factor for Parkinson’s disease [6]. The gene discussed is INS; the disease is Parkinson disease.